Prime Medicine Statistics
Total Valuation
Prime Medicine has a market cap or net worth of $735.25 million. The enterprise value is $753.24 million.
Important Dates
The next estimated earnings date is Friday, November 7, 2025, after market close.
| Earnings Date | Nov 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Prime Medicine has 169.02 million shares outstanding. The number of shares has increased by 24.42% in one year.
| Current Share Class | 169.02M |
| Shares Outstanding | 169.02M |
| Shares Change (YoY) | +24.42% |
| Shares Change (QoQ) | -1.30% |
| Owned by Insiders (%) | 15.76% |
| Owned by Institutions (%) | 30.18% |
| Float | 96.33M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 111.28 |
| Forward PS | n/a |
| PB Ratio | 9.36 |
| P/TBV Ratio | 12.08 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 151.83 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.56, with a Debt / Equity ratio of 1.97.
| Current Ratio | 3.56 |
| Quick Ratio | 2.99 |
| Debt / Equity | 1.97 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -154.81% and return on invested capital (ROIC) is -60.96%.
| Return on Equity (ROE) | -154.81% |
| Return on Assets (ROA) | -47.39% |
| Return on Invested Capital (ROIC) | -60.96% |
| Return on Capital Employed (ROCE) | -83.39% |
| Revenue Per Employee | $23,182 |
| Profits Per Employee | -$931,192 |
| Employee Count | 214 |
| Asset Turnover | 0.02 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +6.62% in the last 52 weeks. The beta is 2.67, so Prime Medicine's price volatility has been higher than the market average.
| Beta (5Y) | 2.67 |
| 52-Week Price Change | +6.62% |
| 50-Day Moving Average | 4.86 |
| 200-Day Moving Average | 3.04 |
| Relative Strength Index (RSI) | 39.04 |
| Average Volume (20 Days) | 4,115,643 |
Short Selling Information
The latest short interest is 15.77 million, so 9.33% of the outstanding shares have been sold short.
| Short Interest | 15.77M |
| Short Previous Month | 20.01M |
| Short % of Shares Out | 9.33% |
| Short % of Float | 16.38% |
| Short Ratio (days to cover) | 3.71 |
Income Statement
In the last 12 months, Prime Medicine had revenue of $4.96 million and -$199.28 million in losses. Loss per share was -$1.57.
| Revenue | 4.96M |
| Gross Profit | -149.46M |
| Operating Income | -204.22M |
| Pretax Income | -199.28M |
| Net Income | -199.28M |
| EBITDA | -197.38M |
| EBIT | -204.22M |
| Loss Per Share | -$1.57 |
Full Income StatementBalance Sheet
The company has $101.75 million in cash and $119.74 million in debt, giving a net cash position of -$17.99 million or -$0.11 per share.
| Cash & Cash Equivalents | 101.75M |
| Total Debt | 119.74M |
| Net Cash | -17.99M |
| Net Cash Per Share | -$0.11 |
| Equity (Book Value) | 60.86M |
| Book Value Per Share | 0.46 |
| Working Capital | 87.18M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$99.94 million and capital expenditures -$7.06 million, giving a free cash flow of -$107.00 million.
| Operating Cash Flow | -99.94M |
| Capital Expenditures | -7.06M |
| Free Cash Flow | -107.00M |
| FCF Per Share | -$0.63 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -4,116.57% |
| Pretax Margin | -4,016.83% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Prime Medicine does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -24.42% |
| Shareholder Yield | -24.42% |
| Earnings Yield | -27.10% |
| FCF Yield | -14.55% |
Analyst Forecast
The average price target for Prime Medicine is $8.88, which is 104.14% higher than the current price. The consensus rating is "Buy".
| Price Target | $8.88 |
| Price Target Difference | 104.14% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | 14.91% |
| EPS Growth Forecast (5Y) | -14.44% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Prime Medicine has an Altman Z-Score of -4.95 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -4.95 |
| Piotroski F-Score | 3 |
